Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.

Kidney international - 1 Dec 2024

Sula Karreci Esilida, Jacas Sonako, Donovan Olivia, Pintye Diana, Wiley Nicholas, Zsengeller Zsuzsanna K, Schlondorff Johannes, Alper Seth L, Friedman David J, Pollak Martin R

Abstract excerpt

Apolipoprotein L1 (APOL1) variants G1 and G2 contribute to the excess risk of kidney disease in individuals of recent African ancestry. Since disease mechanisms and optimal treatments remain controversial, we study the effect of current standard-of-care drugs in mouse models of APOL1 kidney disease. Experiments were performed in APOL1 BAC-transgenic mice, which develop proteinuria and glomerulosclerosis following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors
Share to Apolipoprotein L1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Apolipoproteins

Share to Benzhydryl Compounds

Share to Glomerulosclerosis, Focal Segmental

Share to Glucosides

Share to Lipoproteins, HDL

Share to Proteinuria

Source

Open in PubMed Open full text

Identifiers

PMID: 39181397
DOI: 10.1016/j.kint.2024.07.026
PMCID: PMC11585418

Genes

APOL1
ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.PMID 39181397Read ↗

Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.Semantic proximity Read ↗

Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.Semantic proximity Read ↗

APOL1 kidney risk variants in glomerular diseases modeled in transgenic miceSemantic proximity Read ↗

APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney DiseaseSemantic proximity Read ↗

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.Semantic proximity Read ↗

Strong protective effect of the<i>APOL1</i>p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney diseaseSemantic proximity Read ↗

Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney diseaseSemantic proximity Read ↗

<i>APOL1-G0</i> protects podocytes in a mouse model of HIV-associated nephropathySemantic proximity Read ↗

Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease.Semantic proximity Read ↗

APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.Semantic proximity Read ↗

Small Molecule APOL1 Inhibitors as a Precision Medicine Approach for APOL1-mediated Kidney DiseaseSemantic proximity Read ↗

APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.